- OnCusp Therapeutics secured $100 million Series A funding, co-led by Novo, OrbiMed and F-Prime.
- New board members from lead investors will join the leadership as the 2021-founded startup positions for growth.
- The antibody treatment developer aims to advance medicines translating early research to help combat difficult cancer types.
OnCusp has raised $100M
OnCusp Therapeutics, a US and China-based biopharmaceutical startup has raised $100 million in a Series A funding round to develop its ovarian cancer drug further. The round was co-led by major healthcare investors Novo Holdings, OrbiMed, and F-Prime Capital.
Founded in 2021, OnCusp translates early-stage research into effective cancer medicines. The funding will advance Phase 1 trials for the firm’s antibody drug CUSP06, which aids ovarian cancer treatment. It will also help expand OnCusp’s drug portfolio and team.
Growth and leadership changes
Following the capital raise, new board members from the lead investing firms will join OnCusp’s leadership. This positions the company for continued growth as it progressed from its founding last year when OnCusp raised a $25 million seed round.
The additional funding validates OnCusp’s cancer research and therapeutic approach at an early stage. With seasoned healthcare investors backing its pipeline, the firm aims to develop cutting-edge monoclonal antibody treatments to help combat difficult-to-treat cancers.
